174 related articles for article (PubMed ID: 26817397)
1. TC-PTP and PTP1B: Regulating JAK-STAT signaling, controlling lymphoid malignancies.
Pike KA; Tremblay ML
Cytokine; 2016 Jun; 82():52-7. PubMed ID: 26817397
[TBL] [Abstract][Full Text] [Related]
2. The PTP1B mutant PTP1B∆2-4 is a positive regulator of the JAK/STAT signalling pathway in Hodgkin lymphoma.
Zahn M; Kaluszniak B; Möller P; Marienfeld R
Carcinogenesis; 2021 Apr; 42(4):517-527. PubMed ID: 33382412
[TBL] [Abstract][Full Text] [Related]
3. HiJAKing the epigenome in leukemia and lymphoma.
Drennan AC; Rui L
Leuk Lymphoma; 2017 Nov; 58(11):2540-2547. PubMed ID: 28402164
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.
Maude SL; Dolai S; Delgado-Martin C; Vincent T; Robbins A; Selvanathan A; Ryan T; Hall J; Wood AC; Tasian SK; Hunger SP; Loh ML; Mullighan CG; Wood BL; Hermiston ML; Grupp SA; Lock RB; Teachey DT
Blood; 2015 Mar; 125(11):1759-67. PubMed ID: 25645356
[TBL] [Abstract][Full Text] [Related]
5. Small Molecule Degraders of Protein Tyrosine Phosphatase 1B and T-Cell Protein Tyrosine Phosphatase for Cancer Immunotherapy.
Dong J; Miao J; Miao Y; Qu Z; Zhang S; Zhu P; Wiede F; Jassim BA; Bai Y; Nguyen Q; Lin J; Chen L; Tiganis T; Tao WA; Zhang ZY
Angew Chem Int Ed Engl; 2023 May; 62(22):e202303818. PubMed ID: 36973833
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapeutic implications of negative regulation by protein tyrosine phosphatases in T cells: the emerging cases of PTP1B and TCPTP.
Perez-Quintero LA; Abidin BM; Tremblay ML
Front Med (Lausanne); 2024; 11():1364778. PubMed ID: 38707187
[TBL] [Abstract][Full Text] [Related]
7. A Negative Regulatory Feedback Loop within the JAK-STAT Pathway Mediated by the Protein Tyrosine Phosphatase DUSP14 in Shrimp.
Luo M; Chen N; Han D; Hu B; Zuo H; Weng S; He J; Xu X
J Immunol; 2024 May; ():. PubMed ID: 38767414
[TBL] [Abstract][Full Text] [Related]
8. Predicting gene-level sensitivity to JAK-STAT signaling perturbation using a mechanistic-to-machine learning framework.
Cheemalavagu N; Shoger KE; Cao YM; Michalides BA; Botta SA; Faeder JR; Gottschalk RA
Cell Syst; 2024 Jan; 15(1):37-48.e4. PubMed ID: 38198893
[TBL] [Abstract][Full Text] [Related]
9. Interplay between signal transducers and activators of transcription (STAT) proteins and cancer: involvement, therapeutic and prognostic perspective.
Jill N; Bhootra S; Kannanthodi S; Shanmugam G; Rakshit S; Rajak R; Thakkar V; Sarkar K
Clin Exp Med; 2023 Dec; 23(8):4323-4339. PubMed ID: 37775649
[TBL] [Abstract][Full Text] [Related]
10. The JAK3
Lahera A; Vela-Martín L; Fernández-Navarro P; Llamas P; López-Lorenzo JL; Cornago J; Santos J; Fernández-Piqueras J; Villa-Morales M
Mol Carcinog; 2024 Jan; 63(1):5-10. PubMed ID: 37712558
[TBL] [Abstract][Full Text] [Related]
11. Signaling by STATs.
Ivashkiv LB; Hu X
Arthritis Res Ther; 2004; 6(4):159-68. PubMed ID: 15225360
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a selective TC-PTP degrader for cancer immunotherapy.
Miao J; Dong J; Miao Y; Bai Y; Qu Z; Jassim BA; Huang B; Nguyen Q; Ma Y; Murray AA; Li J; Low PS; Zhang ZY
Chem Sci; 2023 Nov; 14(44):12606-12614. PubMed ID: 38020389
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and structure-activity optimization of azepane-containing derivatives as PTPN2/PTPN1 inhibitors.
Zheng J; Zhang Z; Ding X; Sun D; Min L; Wang F; Shi S; Cai X; Zhang M; Aliper A; Ren F; Ding X; Zhavoronkov A
Eur J Med Chem; 2024 Apr; 270():116390. PubMed ID: 38604096
[TBL] [Abstract][Full Text] [Related]
14. Discovery of PVD-06 as a Subtype-Selective and Efficient PTPN2 Degrader.
Hu L; Li H; Qin J; Yang D; Liu J; Luo X; Ma J; Luo C; Ye F; Zhou Y; Li J; Wang M
J Med Chem; 2023 Nov; 66(22):15269-15287. PubMed ID: 37966047
[TBL] [Abstract][Full Text] [Related]
15. Stem cell-like reprogramming is required for leukemia-initiating activity in B-ALL.
Fregona V; Bayet M; Bouttier M; Largeaud L; Hamelle C; Jamrog LA; Prade N; Lagarde S; Hebrard S; Luquet I; Mansat-De Mas V; Nolla M; Pasquet M; Didier C; Khamlichi AA; Broccardo C; Delabesse É; Mancini SJC; Gerby B
J Exp Med; 2024 Jan; 221(1):. PubMed ID: 37930337
[TBL] [Abstract][Full Text] [Related]
16. Potential network markers and signaling pathways for B cells of COVID-19 based on single-cell condition-specific networks.
Li Y; Han L; Li P; Ge J; Xue Y; Chen L
BMC Genomics; 2023 Oct; 24(1):619. PubMed ID: 37853311
[TBL] [Abstract][Full Text] [Related]
17. Single-cell CRISPR screening characterizes transcriptional deregulation in T-cell acute lymphoblastic leukemia.
Meyers S; Gielen O; Cools J; Demeyer S
Haematologica; 2024 May; ():. PubMed ID: 38813729
[TBL] [Abstract][Full Text] [Related]
18. Predicting gene level sensitivity to JAK-STAT signaling perturbation using a mechanistic-to-machine learning framework.
Cheemalavagu N; Shoger KE; Cao YM; Michalides BA; Botta SA; Faeder JR; Gottschalk RA
bioRxiv; 2023 May; ():. PubMed ID: 37292918
[TBL] [Abstract][Full Text] [Related]
19. Structural and mutational analysis of member-specific STAT functions.
Erdogan F; Qadree AK; Radu TB; Orlova A; de Araujo ED; Israelian J; Valent P; Mustjoki SM; Herling M; Moriggl R; Gunning PT
Biochim Biophys Acta Gen Subj; 2022 Mar; 1866(3):130058. PubMed ID: 34774983
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies.
Sun R; Wang J; Young KH
Crit Rev Oncog; 2017; 22(5-6):527-557. PubMed ID: 29604930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
